Plus Therapeutics Stock Forum

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Tuesday, 17th December at 7:30 am
Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation
Both single-dose and multiple-dose expansion trials planned in 2025
AUSTIN, Texas, Dec. 17...

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Plus Therapeutics (PSTV) will present Phase 1 interim data for its ReSPECT-LM trial at the 2024 San Antonio Breast Cancer Symposium. The presentation will focus on Rhenium (186Re) Obisbemeda treatment for leptomeningeal metastases (LM) in breast cancer patients.
The presentation, led by Dr. Andrew Brenner from the Unive...

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Tuesday, 3rd December at 7:30 am
AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. (‘IsoTherapeutics', a Telix Group...

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints
CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases
Assay demonstrated 2.8 times the diagnost...

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Rhenium (186Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy
Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy
ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New Y...

$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
CNSide in...

$Plus Therapeutics (PSTV.US)$ Benzinga· 1 min ago
Plus Therapeutics Presented Data In Podium Presentation Updating The Progress Of Its ReSPECT-LM Trial Of Rhenium Obisbemeda In Leptomeningeal Disease At The 2024 Society For NeuroOncology/American Society For Clinical Oncology CNS Metastases Conference

$Plus Therapeutics (PSTV.US)$ Plus Therapeutics (PSTV) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded in September 2022.
The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.